Current and future therapies for SLE: Obstacles and recommendations for the development of novel treatments

Lupus Science and Medicine

Volumn 4, Issue 1, 2017, Pages

  Touma, Zahi ^a   Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

cytokines; interferon; lupus nephritis; systemic lupus erythematosus; treatment

Indexed keywords

ABATACEPT; ANIFROLUMAB; ATACICEPT; FORIGERIMOD; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; VOCLOSPORIN;

HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION;

EID: 85057229374     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2017-000239     Document Type: Review

References (69)

1. Dema B, Charles N. Advances in mechanisms of systemic lupus erythematosus. Discov Med 2014;17:247-55.
2. Liu Z, Davidson A. Taming lupus-A new understanding of pathogenesis is leading to clinical advances. Nat Med 2012;18:871-82.
3. Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.
4. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012;14(Suppl 4):S4.
5. Tunnicliffe DJ, Singh-Grewal D, Kim S, et al. Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res 2015;67:1440-52.
6. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
7. Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 2012;64:2-8.
8. GlaxoSmithKline LLC. Benlysta (belimumab) prescribing information. 2017 https://www. gsksource. com/ pharma/ content/ dam/ GlaxoSmithKline/ US/ en/ Prescribing Information/ Benlysta/ pdf/ BENLYSTA-PI-MG. PDF (accessed 26 Oct 2017).
9. Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res 2011;317:1270-7.
10. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
11. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
12. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
13. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
14. Furie RA, Wallace DJ, Aranow C, et al. 7-year safety and efficacy of belimumab in patients with systemic lupus erythematosus. Arthritis Rheumatol 2016;68(Suppl 10):P768.
15. Collins CE, Dall'Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 2016;3:e000118.
16. Touma Z, Sayani A, Pineau CA, et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int 2017;37:865-73.
17. Schwarting A, Schroeder JO, Alexander T, et al. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in germany: results from the OBSErve Germany study. Rheumatol Ther 2016;3:271-90.
18. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2017;69:1016-27.
19. ClinicalTrials. gov. ClinicalTrials. gov is a database of privately and publicly funded clinical studies conducted around the world. https://www. clinicaltrials. gov/ (accessed 26 Oct 2017).
20. ISRCTN Registry. isrctn. com. Comparison of two methods of lymph node removal in patients suffering from lung cancer. http://www. isrctn. com (accessed 13 Sep 2017).
21. Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunology 2016;5:e79.
22. Cucak H, Yrlid U, Reizis B, et al. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009;31:491-501.
23. Bacher N, Raker V, Hofmann C, et al. Interferon-α suppresses cAMP to disarm human regulatory T cells. Cancer Res 2013;73:5647-56.
24. Agrawal H, Jacob N, Carreras E, et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009;183:6021-9.
25. Liu Z, Bethunaickan R, Huang W, et al. Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum 2011;63:219-29.
26. Dall'era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-7.
27. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
28. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol 2017;69:376-86.
29. Merrill J, Furie R, Werth VP, et al. The effect of anifrolumab on cutaneous manifestations and arthritis in moderate to severe systemic lupus erythematosus (SLE) using categorical SLEDAI-2K responses and continuous measures of activity as outcome measures [abstract]. Arthritis Rheumatol 2016;68(Suppl 10):P2009.
30. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015;74:2006-15.
31. Gordon C, Wofsy D, Wax S, et al. Post hoc analysis of the phase II/ III april-sle study: association between response to atacicept and serum biomarkers including BLyS and april. Arthritis Rheumatol 2017;69:122-30.
32. Merck KGaA Press Release. Merck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II results confirm potential of atacicept as a candidate therapy for SLE. 2016 http:// news. emdgroup. com/ EMD/ CC/ EMDNewsRelease. nsf/ Open (accessed 7 Apr 2017).
33. Suárez-Fueyo A, Bradley SJ, Tsokos GC. T cells in systemic lupus erythematosus. Curr Opin Immunol 2016;43:32-8.
34. Xu H, Liu J, Cui X, et al. Increased frequency of circulating follicular helper T cells in lupus patients is associated with autoantibody production in a CD40L-dependent manner. Cell Immunol 2015;295:46-51.
35. Zhang X, Lindwall E, Gauthier C, et al. Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. Lupus 2015;24:909-17.
36. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989;143:103-12.
37. Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379-89.
38. Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201:703-11.
39. Wardemann H, Nussenzweig MC. B-cell self-tolerance in humans. Adv Immunol 2007;95:83-110.
40. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-33.
41. Cappione A, Anolik JH, Pugh-Bernard A, et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005;115:3205-16.
42. Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797-808.
43. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
44. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64:1215-26.
45. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20:709-16.
46. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.
47. Zimmer R, Scherbarth HR, Rillo OL, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, doubleblind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013;72:1830-5.
48. Aurinia Pharmaceuticals Inc. Aurinia announces voclosporin meets 48-week remission endpoints, achieving highest complete remission rate of any global lupus nephritis study. http:// ir. auriniapharma. com/ press-releases/ detail/ 73 (accessed 13 Sep 2017).
49. Clowse ME, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase iii randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol 2017;69:362-75.
50. Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:323-31.
51. Medina-Rosas J, Al-Rayes H, Moustafa AT, et al. Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials. Expert Opin Biol Ther 2016;16:1225-38.
52. Rodríguez-Pintó I, Espinosa G, Cervera R. The problems and pitfalls in systemic lupus erythematosus drug discovery. Expert Opin Drug Discov 2016;11:525-7.
53. Touma Z, Gladman DD, Ibañez D, et al. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol 2011;38:275-84.
54. Touma Z, Urowitz MB, Taghavi-Zadeh S, et al. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months. Rheumatology 2012;51:1814-9.
55. Touma Z, Gladman DD, Ibañez D, et al. SLEDAI-2K Responder Index 50. captures 50% improvement in disease activity over 10 years. Lupus 2012;21:1305-11.
56. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-lupus nephritis cohort. Arthritis Rheumatol 2015;67:1305-13.
57. Karassa FB, Tatsioni A, Ioannidis JP, Design IJP. Design, quality, and bias in randomized controlled trials of systemic lupus erythematosus. J Rheumatol 2003;30:979-84.
58. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol 2006;18:476-80.
59. Touma Z, Urowitz MB, Ibañez D, et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol 2014;41:688-97.
60. Petri MA, van Vollenhoven RF, Buyon J, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143-53.
61. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183-90.
62. Touma Z, Gladman DD, Su J, et al. SLE disease activity index glucocorticoid index (SLEDAI-2KG) identifies more responders than SLEDAI-2K. Arthritis Rheum 2017;69 (Suppl 10):P1624.
63. Abrahamowowicz M, Esdaile JM, Ramsey-Goldman R, et al. Development and validation of a novel evidence-based lupus multivariable outcome score for clinical trials. [abstract]. Arthritis Rheum 2017;69 (Suppl 10):P1839.
64. Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:332-40.
65. University Health Network. Improving the assessment of SLE disease activity. 2017 https:// clinicaltrials. gov/ ct2/ show/ NCT03144063 (accessed 15 Sep 2017).
66. Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a 24-week randomized, placebo-controlled, phase iib study. Arthritis Rheumatol 2017;68 (Suppl 10):P12L.
67. Urowitz MB, Isenberg DA, Wallace DJ. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med 2015;2:e000104.
68. Tillmanns S, Kolligs C, D'Cruz DP, et al. SM101, a novel recombinant, soluble, human FcγIIB receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study. Arthritis Rheum 2014;66 (S1238):P2833.
69. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomized placebo-controlled study. Arthritis Rheum 2017;69 (Suppl 10):P6L.